ACI’s 2nd Annual Summit on GLP-1 Law & Policy April 20, 2026

https://www.thefdalawblog.com/2026/04/acis-2nd-annual-summit-on-glp-1-law-policy/?utm_source=rss&utm_medium=rss&utm_campaign=acis-2nd-annual-summit-on-glp-1-law-policy The GLP-1 market is set to hit over $30 billion by 2030. Intellectual property litigation and FDA crackdowns have led to a boom in M&A and partnership activity. Long-term patient effects have yet to be fully realized. The future of GLP-1s is bright, but ownership, liability, and regulatory priorities still hang in the balance. That’s the backdrop for the American Conference Institute’s (“ACI”) 2nd Annual Summit on GLP-1 Law & Policy, which returns on June 4, 2026, at 3 Times Square, New York, NY.